Company intelligence / Profile preview

Cohesyx Bio

San Diego, California, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Cohesyx Bio is developing novel immune cell-targeted antibody-drug conjugates using its Rx2 platform. The approach aims to activate or suppress immune responses for cancer and inflammatory diseases by leveraging clinically validated antibodies as delivery vehicles for drug payloads. This strategy seeks to reduce toxicity and improve efficacy through targeted delivery and additive/synergistic effects from combining proven antibodies with new payloads. No clinical results are reported yet; the company appears preclinical.

Therapeutic areas: ImmunologyOncology
Modalities: Antibody-drug conjugateAntibody
Industry: Biotech

Beyond the preview

Go deeper on Cohesyx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cohesyx Bio.

Explore the full profile